

IN THE CLAIMS

1-10. (Cancelled).

11. (Currently Amended) A punctal plug comprising:

a plug body, including a porous or absorbent material, the plug body sized and shaped for at least partial insertion into a lacrimal punctum and extending from a proximal end portion to a distal end portion; and

an active agent disposed substantially throughout an exterior surface of the plug body from approximately the proximal end portion to approximately the distal end portion, the active agent configured to provide a sustained release to tissue at or near one or both of an eye or a nasolacrimal system of a subject via an exposed medication-discharging supply.

12. (Previously Presented) The punctal plug of claim 11, wherein the active agent is disposed substantially throughout the plug body from approximately the proximal end portion to approximately the distal end portion.

13. (Withdrawn – Currently Amended) The punctal plug of claim 11, wherein the distal end portion of the plug body includes a stem, the stem configured to insert into a canaliculus of the subject and including the exposed medication-discharging supply of the active agent at one or more external surfaces thereof.

14. (Previously Presented – Currently Amended) The punctal plug of claim 11, wherein the proximal end portion of the plug body includes an outer stopper structure extending at least partially from or around an outer body surface and configured to seat against the lacrimal punctum, the outer stopper structure including the exposed medication-discharging supply of the active agent at one or more external surfaces thereof.

15. (Previously Presented) The punctal plug of claim 11, wherein the active agent includes a

medicine.

16. (Withdrawn – Currently Amended) The punctal plug of claim 15, wherein the active agent includes a medicine selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimatoprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a medication for treating hypertension; atenolol; nifedipine; ~~and~~ hydrochlorothiazide; cyclosporine; and olopatadine.

17. (Currently Amended) The punctal plug of claim 11, wherein the active agent includes a medication for ~~the topical~~ treatment of ~~glaucoma~~ an eye.

18. (Withdrawn) The punctal plug of claim 11, wherein the plug body includes a lumen extending from the proximal end portion to the distal end portion, the lumen configured for a passage of tear fluid therethrough.

19. (Withdrawn – Currently Amended) The punctal plug of claim 18, ~~comprising an~~ wherein ~~the~~ exposed medication-discharging supply of the active agent ~~is~~ disposed on at least one portion of the lumen wall, the active agent configured to treat the nasolacrimal system.

20. (Previously Presented) The punctal plug of claim 11, wherein the entire plug body is saturated with the active agent.

21. (Previously Presented – Currently Amended) The punctal plug of claim 11, ~~comprising an~~ wherein the exposed medication-discharging supply of the active agent ~~is~~ disposed on at least one external surface of the proximal end portion of the plug body, the active agent configured to treat the eye.

22. (Previously Presented) The punctal plug of claim 21, wherein the exposed medication-discharging supply of the active agent is configured to provide the sustained release to tissue at or

near the eye for a time period of at least about 3 months after implant.

23. (Previously Presented) The punctal plug of claim 21, wherein the exposed medication-discharging supply of the active agent includes one or more agent-discharging bands.

24. (Withdrawn – Currently Amended) The punctal plug of claim 11, ~~comprising an~~ wherein the exposed medication-discharging supply of the active agent is disposed on at least one external surface of the distal end portion, the active agent configured to treat, at least in part, the nasolacrimal system.

25. (Withdrawn) The punctal plug of claim 24, wherein the exposed medication-discharging supply of the active agent includes one or more agent-discharging bands.

26. (Previously Presented – Currently Amended) The punctal plug of claim 11, ~~comprising an~~ wherein the exposed medication-discharging supply of the active agent is disposed on all external surfaces of the plug body.

27. (Previously Presented) The punctal plug of claim 11, wherein the distal end portion of the plug body includes an inner stopper structure, the inner stopper structure configured to at least partially secure an implant location of the plug body.

28. (Withdrawn) The punctal plug of claim 13, wherein the exposed medication-discharging supply of the active agent is configured to provide the sustained release to tissue of the canaliculus wall.

29. (Previously Presented) The punctal plug of claim 14, wherein the outer stopper structure is configured to completely seal the lacrimal punctum against a flow of tear fluid therethrough.

30. (Previously Presented) A punctal plug comprising:
a plug body, sized and shaped for at least partial insertion into a lacrimal punctum; and
an exposed medication-discharging supply of an active agent at least partially disposed on
at least one external surface of the plug body, the exposed medication-discharging supply
configured to provide a sustained release of the active agent to one or both of an eye or a
nasolacrimal system for a time period of at least about 3 months after implant..
31. (Previously Presented) The punctal plug of claim 30, wherein the exposed medication-
discharging supply of the agent is disposed on at least one surface of a proximal end portion of
the plug body, the active agent configured to treat the eye.
32. (Withdrawn) The punctal plug of claim 30, wherein the exposed medication-discharging
supply of the agent is disposed on at least one surface of a distal end portion of the plug body, the
active agent configured to treat the nasolacrimal system.
33. (Previously Presented) The punctal plug of claim 30, wherein a distal end portion of the
plug body includes an inner stopper structure configured to at least partially secure an implant
location of the plug body.
34. (Previously Presented) The punctal plug of claim 30, wherein the entire plug body is
substantially saturated with the active agent.
35. (Previously Presented) The punctal plug of claim 34, wherein the exposed medication-
discharging supply of the agent is disposed on all external surfaces of the plug body.
36. (Withdrawn – Currently Amended) The punctal plug of claim 30, wherein the active
agent includes a medicine selected from the group comprising: topical prostaglandin; latanoprost;
travaprost; bimatoprost; a medication for a treatment for corneal infections; ciprofloxacin;
moxifloxacin; gatifloxacin; a systemic medication; a medication for treating hypertension;

atenolol; nifedipine; and hydrochlorothiazide; cyclosporine; and olopatadine.